Surgical Treatment of Refractory Open Angle Glaucoma
Primary Purpose
Open Angle Glaucoma
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Suprachoroidal Dissection Instrument (SDI)
Sponsored by
About this trial
This is an interventional treatment trial for Open Angle Glaucoma
Eligibility Criteria
Inclusion Criteria:
- Available for up to 3 years follow-up.
- Diagnosed with primary open-angle, pseudoexfoliative, or pigmentary glaucoma or more than one glaucoma diagnosis of these types.
- Subject scheduled to undergo glaucoma surgery with the Suprachoroidal Dissection Instrument involving creation of fistula between Schlemm's canal and the suprachoroidal space without combined cataract surgery.
- Subject has failed at least one incisional glaucoma surgery (trabeculectomy, tube shunt, deep sclerectomy, viscocanalostomy, canaloplasty) or angle surgery (Trabectome) OR Is not a candidate for conventional glaucoma surgery due to reasons such as the presence of scleral buckle or compromised conjunctiva.
- Subject has IOP ≥ 16 mm Hg on maximally tolerated medications within the six week (-42 days) period prior to surgery.
- Visual field defect defined as mean deviation (MD) score worse than or equal to -10 dB on the Swedish Interactive Threshold Algorithm [SITA] Standard 24-2 Humphrey Analysis during the 6 month period prior to surgery. OR Subject has vertical cup-to-disk ratio ≥ 0.75 during the 6 month period prior to surgery.
Exclusion Criteria:
- Significant lens opacities or patient is candidate for cataract surgery during the duration of the study.
- The patient had developmental glaucoma or a secondary glaucoma including steroid-induced, uveitic, or neovascular glaucoma (with the exception of pigmentary and pseudoexfoliative glaucoma).
- The patient has narrow angle component possibly associated with glaucoma in the operative eye.
- The subject has angle recession in the operative eye.
- Significant ocular disease other than glaucoma affecting the assessment of visual function.
Sites / Locations
- Glaucoma Associates of Texas
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Suprachoroidal Dissection Instrument
Arm Description
Outcomes
Primary Outcome Measures
Postoperative intraocular pressure, glaucoma medication usage, and visual acuity
Secondary Outcome Measures
Full Information
NCT ID
NCT01212861
First Posted
September 29, 2010
Last Updated
September 11, 2012
Sponsor
iScience Interventional Corporation
1. Study Identification
Unique Protocol Identification Number
NCT01212861
Brief Title
Surgical Treatment of Refractory Open Angle Glaucoma
Official Title
Surgical Treatment of Refractory Open Angle Glaucoma - A Prospective, Open-Label, Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
May 2012 (Actual)
Study Completion Date
May 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
iScience Interventional Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to evaluate the safety, efficacy, and performance of the Suprachoroidal Dissection Instrument in creating a fistula between Schlemm's canal and the suprachoroidal space in refractory, open angle glaucoma subjects.
Detailed Description
The Suprachoroidal Dissection Instrument (SDI) is a manually operated surgical instrument designed for use within Schlemm's canal. The instrument can access Schlemm's canal through a small ab-externo dissection, allowing use in eyes with scarring due to previous surgery or trauma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open Angle Glaucoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Suprachoroidal Dissection Instrument
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Suprachoroidal Dissection Instrument (SDI)
Other Intervention Name(s)
SDI
Intervention Description
The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
Primary Outcome Measure Information:
Title
Postoperative intraocular pressure, glaucoma medication usage, and visual acuity
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Available for up to 3 years follow-up.
Diagnosed with primary open-angle, pseudoexfoliative, or pigmentary glaucoma or more than one glaucoma diagnosis of these types.
Subject scheduled to undergo glaucoma surgery with the Suprachoroidal Dissection Instrument involving creation of fistula between Schlemm's canal and the suprachoroidal space without combined cataract surgery.
Subject has failed at least one incisional glaucoma surgery (trabeculectomy, tube shunt, deep sclerectomy, viscocanalostomy, canaloplasty) or angle surgery (Trabectome) OR Is not a candidate for conventional glaucoma surgery due to reasons such as the presence of scleral buckle or compromised conjunctiva.
Subject has IOP ≥ 16 mm Hg on maximally tolerated medications within the six week (-42 days) period prior to surgery.
Visual field defect defined as mean deviation (MD) score worse than or equal to -10 dB on the Swedish Interactive Threshold Algorithm [SITA] Standard 24-2 Humphrey Analysis during the 6 month period prior to surgery. OR Subject has vertical cup-to-disk ratio ≥ 0.75 during the 6 month period prior to surgery.
Exclusion Criteria:
Significant lens opacities or patient is candidate for cataract surgery during the duration of the study.
The patient had developmental glaucoma or a secondary glaucoma including steroid-induced, uveitic, or neovascular glaucoma (with the exception of pigmentary and pseudoexfoliative glaucoma).
The patient has narrow angle component possibly associated with glaucoma in the operative eye.
The subject has angle recession in the operative eye.
Significant ocular disease other than glaucoma affecting the assessment of visual function.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronald Fellman, MD
Organizational Affiliation
Glaucoma Associates of Texas
Official's Role
Principal Investigator
Facility Information:
Facility Name
Glaucoma Associates of Texas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Surgical Treatment of Refractory Open Angle Glaucoma
We'll reach out to this number within 24 hrs